Table 2.
Characterization parameters of MSNs, MSNs-NH2, MSNs-anti-miR-155, and MSNs-anti-miR-155@PDA-Apt
| Sample | Sizea (nm) | Zeta potential (mV) |
BET surface area (m2/g) | Pore volumeb (cm3/g) |
Pore sizec (nm) |
|---|---|---|---|---|---|
| MSNs | 125.53±5.46 | -16.11±4.25 | 232.45 | 0.62 | 2.83 |
| MSNs-NH2 | 126.02±3.48 | 3.11±4.25 | 227.26 | 0.59 | 2.80 |
| MSNs-anti-miR-155 | 130.57±3.74 | -10.57±3.42 | 157.35 | 0.38 | 2.12 |
| MSNs-anti-miR-155@PDA-Apt | 182.75±4.76 | -15.65±6.26 | 58.56 | 0.21 | – |
Notes:
a
Nanoparticle size was measured by dynamic light scattering. Data are expressed as mean ± SD.
b
Barrett–Joyner–Halenda (BJH) cumulative pore volume for pores between 1.7 and 300 nm in width.
c
Most probable pore size.
Abbreviations: MSNs, mesoporous silica nanoparticles; PDA, polymerized dopamine; Apt, aptamer; BET, Brunauer–Emmett–Teller; SD, standard deviation; miR-155, MicroRNA-155.